159 related articles for article (PubMed ID: 37276599)
41. Genomic Variation and Pharmacokinetics in Old Age: A Quantitative Review of Age- vs. Genotype-Related Differences.
Dücker CM; Brockmöller J
Clin Pharmacol Ther; 2019 Mar; 105(3):625-640. PubMed ID: 29498032
[TBL] [Abstract][Full Text] [Related]
42. Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM; Goey AK; Ley AM; Strope JD; Figg WD
Methods Mol Biol; 2014; 1175():91-120. PubMed ID: 25150868
[TBL] [Abstract][Full Text] [Related]
43. Germline genetic testing to predict drug response and toxicity in oncology--reality or fiction?
Soh TI; Yong WP
Ann Acad Med Singap; 2011 Aug; 40(8):350-5. PubMed ID: 22065000
[TBL] [Abstract][Full Text] [Related]
44. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
[TBL] [Abstract][Full Text] [Related]
45. Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia.
Koutsilieri S; Tzioufa F; Sismanoglou DC; Patrinos GP
Pharmacol Res; 2020 Mar; 153():104590. PubMed ID: 31830522
[TBL] [Abstract][Full Text] [Related]
46. A clinical approach to pharmacogenetics.
de Graaff LC; van Schaik RH; van Gelder T
Neth J Med; 2013 Apr; 71(3):145-52. PubMed ID: 23712814
[TBL] [Abstract][Full Text] [Related]
47. Drug-induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies.
Lanvers-Kaminsky C; Zehnhoff-Dinnesen AA; Parfitt R; Ciarimboli G
Clin Pharmacol Ther; 2017 Apr; 101(4):491-500. PubMed ID: 28002638
[TBL] [Abstract][Full Text] [Related]
48. Protocol for a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of independent pharmacist prescribing in care homes: the CHIPPS study.
Bond CM; Holland R; Alldred DP; Arthur A; Barton G; Blyth A; Desborough J; Ford J; Handford C; Hill H; Hughes CM; Maskrey V; Massey K; Myint PK; Norris N; Poland FM; Shepstone L; Turner D; Zermansky A; Wright D;
Trials; 2020 Jan; 21(1):103. PubMed ID: 31964398
[TBL] [Abstract][Full Text] [Related]
49. Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis.
Reid P; Danahey K; Lopez Velazquez M; Ratain MJ; O'Donnell PH
Clin Exp Rheumatol; 2021; 39(6):1385-1393. PubMed ID: 33506753
[TBL] [Abstract][Full Text] [Related]
50. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation.
Duconge J; Ruaño G
Pharmacogenomics; 2015; 16(15):1685-8. PubMed ID: 26431456
[No Abstract] [Full Text] [Related]
51. Clinical pharmacogenetics: how do we ensure a favorable future for patients?
Wiltshire T; Dong OM
Pharmacogenomics; 2018 Apr; 19(6):553-562. PubMed ID: 29620450
[TBL] [Abstract][Full Text] [Related]
52. Herbal Remedies: Throwing Off Phenotype Prediction-A Culprit for Pharmacogenomic-Guided Drug Therapy and Drug Safety.
Dandara C; Thomford NE; Bapiro TE
Clin Pharmacol Ther; 2019 Aug; 106(2):302-304. PubMed ID: 31245840
[No Abstract] [Full Text] [Related]
53. Clinical Utility and Economic Impact of CYP2D6 Genotyping.
Reynolds KK; McNally BA; Linder MW
Clin Lab Med; 2016 Sep; 36(3):525-42. PubMed ID: 27514466
[TBL] [Abstract][Full Text] [Related]
54. Protocol for the process evaluation of a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of independent pharmacist prescribing in care home: the CHIPPS study.
Bond CM; Holland R; Alldred DP; Arthur A; Barton G; Birt L; Blyth A; Desborough J; Ford J; Handford C; Hill H; Hughes CM; Maskrey V; Massey K; Myint PK; Norris N; Poland FM; Shepstone L; Zermansky A; Wright D;
Trials; 2020 May; 21(1):439. PubMed ID: 32471514
[TBL] [Abstract][Full Text] [Related]
55. [Ethics on genetic research (1). Pharmacogenetic studies].
Ayuso C; Abad-Santos F; Dal-Ré R; Gracia D
Med Clin (Barc); 2011 May; 136(15):678-82. PubMed ID: 20044101
[No Abstract] [Full Text] [Related]
56. Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.
Vassy JL; Chun S; Advani S; Ludin SA; Smith JG; Alligood EC
Clin Pharmacol Ther; 2019 Aug; 106(2):360-373. PubMed ID: 30137643
[TBL] [Abstract][Full Text] [Related]
57. Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?
Huddart R; Sangkuhl K; Whirl-Carrillo M; Klein TE
Clin Pharmacol Ther; 2019 Aug; 106(2):284-286. PubMed ID: 30977517
[No Abstract] [Full Text] [Related]
58. Identifying genomic and developmental causes of adverse drug reactions in children.
Becker ML; Leeder JS
Pharmacogenomics; 2010 Nov; 11(11):1591-602. PubMed ID: 21121777
[TBL] [Abstract][Full Text] [Related]
59. Pharmacogenetics in drug regulation: promise, potential and pitfalls.
Shah RR
Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1617-38. PubMed ID: 16096112
[TBL] [Abstract][Full Text] [Related]
60. The role of pharmacogenomics in adverse drug reactions.
Cacabelos R; Cacabelos N; Carril JC
Expert Rev Clin Pharmacol; 2019 May; 12(5):407-442. PubMed ID: 30916581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
